Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant

Who could benefit from this research

What this research studies

After a stem cell transplant from a partially matched donor, relapse of AML or MDS is common and deadly. The study builds on prior work showing that IFN-γ signaling helps donor immune cells target leukemia cells while aiming to limit graft-versus-host disease. In patients who relapse after haploidentical transplantation, the team will evaluate safety and initial effectiveness of combining IFN-γ with donor lymphocyte infusions. The trial leverages learnings from prior trials in matched donors and preclinical data to inform this haploidentical setting. If successful, this approach could improve durable remissions for people with relapsed AML/MDS after haploidentical transplants.

Why it matters

Where this research is happening

• University of Pittsburgh at Pittsburgh
  Pittsburgh, United States Active

Researchers

• Principal investigator: Ito, Sawa — University of Pittsburgh at Pittsburgh
• Study coordinator: Ito, Sawa

Related research

Other NIH-funded projects on the same topics.

• Targeting the SCP4 pathway in acute myeloid leukemia (AML)

  Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.

  NIH research St. Jude Children's Research Hospital · Memphis, United States · NIH-11617813

• Targeting the protein housekeeping system in adult leukemia

  Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.

  NIH research University of California, San Diego · La Jolla, United States · NIH-11452453

• Understanding how epigenetic helper proteins drive AML and how to target them

  A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.

  NIH research University of Alabama at Birmingham · Birmingham, United States · NIH-11448341

• Targeting FLVCR1-enabled choline use in a aggressive AML subtype

  A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.

  NIH research Seattle Children's Hospital · Seattle, United States · NIH-11427960

• Advancing CD70-targeted CAR-NK Therapy for AML

  A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11425793

• New drug target pathway to fight acute myeloid leukemia (AML) by disrupting selenium use

  A new grant explores how AML cells depend on selenium metabolism and how blocking certain regulators can trigger cancer cell death, with potential benefits for adults with AML.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11424976

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.